|
ProBiotix Health PLC on Wednesday said sales growth was driven by the US and Europe but cautioned that the re-ignited trade war between the US and UK/Europe could have a short-term negative impact. The Wakefield, England-based life sciences firm said gross profit grew 46% to £1.5 million in 2025 from £997,000 the year prior as sales increased 45% to £2.7 million from £1.9 million. Loss before interest, tax, depreciation and amortisation narrowed to £445,000 from £642,000. The company noted a ‘strong’ cash balance of £1.3 million at year-end, and a record first quarter 2026 order book of £1.3 million, more than doubled year-on-year. ‘The strong trading performance reflects growing commercial traction across our core markets, supported by both new customer acquisition, and continued positive growth from already established customer partnerships,’ the firm said in a statement. Revenue growth was primarily driven by increased traction in the US and Europe, with the relationship with ‘key’ US customer Seed Health Inc ‘robust’ and delivering continued growth. During 2026, the company’s commercial focus will include accelerated expansion across the Asia-Pacific region, which ‘management believes will be a key driver of short- and medium-term revenue growth as well as serve as risk mitigation towards the re-ignited trade war between the US and UK/Europe.’ ‘We believe the current trade situation might potentially have a negative short term impact on the speed at which we can penetrate the US-market in 2026. However, no long term impact is anticipated, with the mitigation measure of local manufacturing being executed,’ it added. Shares in ProBiotix Health were flat at 7.75 pence each in London on Wednesday. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
